Advertisement

Tumor Biology

, Volume 36, Issue 4, pp 3017–3023 | Cite as

Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer

  • Jing Zhou
  • Zhi-yue Liu
  • Cun-bao Li
  • Shang Gao
  • Li-hong Ding
  • Xin-lin Wu
  • Zhao-yang Wang
Research Article

Abstract

We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms. A number of 415 patients of gastric cancer that received platinum-based chemotherapy were enrolled in the present study. The presence of ERCC1 rs11615 and rs2298881, ERCC2 rs1799793 and rs13181, NBN rs1805794, rs709816, and RAD51 rs1801321 and XRCC3 rs1799794 were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Conditional regression analysis identified that CC genotype of ERCC1 rs11615 and AA genotype of ERCC2 rs1799793 was associated with a better response to chemotherapy in gastric cancer patients, and the odds ratio (ORs)(95% confidence interval (CI)) were 2.70(1.33–5.70) and 3.12(1.52–6.84), respectively. By the Cox analysis, the CC genotype of ERCC1 rs11615, AA genotype of ERCC2 rs1799793, and CC genotype of NBN rs1805794 were significantly associated with a longer overall survival (OS) of gastric cancer. In conclusion, our results suggest that ERCC1 rs11615, ERCC2 rs1799793, and NBN rs1805794 polymorphisms in the DNA repair pathways may influence the response to chemotherapy and OS of gastric cancer.

Keywords

Single nucleotide polymorphism DNA repair pathway Gastric cancer Chemotherapy Overall survival 

Notes

Conflicts of interest

None

References

  1. 1.
    Stomach Cancer. Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, 2014.
  2. 2.
    International Agency for Research on Cancer. IARC working group on the evaluation of carcinogenic risks to humans, schistosomes, liver flukes, Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 61. Lyon: International Agency for Research on Cancer; 1994. p. 1–241.Google Scholar
  3. 3.
    Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 2004;54 Suppl 1:S4–11.PubMedGoogle Scholar
  4. 4.
    Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 1991;18(1 Suppl 3):11–24.PubMedGoogle Scholar
  5. 5.
    Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly. 2011;141:w13275.PubMedGoogle Scholar
  6. 6.
    Liu L, Li CH, Jin TF, Xu DY. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Genet Mol Res. 2014;13(4):8722–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang X, Bai Z, Chen B, Feng J, Yan F, Jiang Z, et al. Polymorphism of methylenetetrahydrofolate reductase gene is associated with response to fluorouracil-based chemotherapy in Chinese patients with gastric cancer. Chin Med J (Engl). 2014;127(20):3562–7.Google Scholar
  8. 8.
    Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 2013;13:43.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xu J, Ma J, Zong HT, Wang SY, Zhou JW. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis. Genet Mol Res. 2014;13(1):1438–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Lu ZM, Luo TH, Nie MM, Fang GE, Ma LY, Xue XC, et al. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Tumour Biol. 2014;35(4):2941–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Marsh S, McLeod H, Dolan E, Shukla SJ, Rabik CA, Gong L, et al. Platinum pathway. Pharmacogenet Genomics. 2009 Jul;19(7):563–4.Google Scholar
  12. 12.
    Enoiu M, Jiricny J, Scharer OD. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Res. 2012;40(18):8953–64.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, et al. Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis. 2013;34(10):2314–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest. 2009;119(7):1974–85.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu L, Li CH, Jin TF, Xu DY. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Genet Mol Res. 2014;13(4):8722–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen ZH, Wang L, Luo LP. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer. Genet Mol Res. 2014;13(3):7484–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Li J, Zuo X, Lv X, Kong F, Xu W, Yang S. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population. Tumour Biol. 2014;35(8):7569–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Lu ZM, Luo TH, Nie MM, Fang GE, Ma LY, Xue XC, et al. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Tumour Biol. 2014;35(4):2941–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Chu H, Gu D, Xu M, Xu Z, Gong Y, Gong W, et al. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. Mutagenesis. 2013;28(4):441–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, et al. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013;8(9):e71994.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001;61(4):1354–7.PubMedGoogle Scholar
  23. 23.
    Goricar K, Erculj N, Zadel M, Dolzan V. Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. Radiol Oncol. 2012;46(1):46–53.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014;24(10):514–21.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jing Zhou
    • 1
  • Zhi-yue Liu
    • 2
  • Cun-bao Li
    • 3
  • Shang Gao
    • 4
  • Li-hong Ding
    • 5
  • Xin-lin Wu
    • 6
  • Zhao-yang Wang
    • 6
  1. 1.Department of Pharmacology, Basic Medicine CollegeInner Mongolia Medical UniversityHohhotChina
  2. 2.Department of Pathophysiology, Basic Medicine CollegeInner Mongolia Medical UniversityHohhotChina
  3. 3.Department of Biochemistry, Basic Medicine CollegeInner Mongolia Medical UniversityHohhotChina
  4. 4.Department of Anatomy, Basic Medicine CollegeInner Mongolia Medical UniversityHohhotChina
  5. 5.Department of Internal MedicineAffiliated Hospital of Inner Mongolia Medical UniversityHohhotChina
  6. 6.Department of General SurgeryAffiliated Hospital of Inner Mongolia Medical UniversityHohhotChina

Personalised recommendations